Datasheet | January 24, 2022

Viral Vector Manufacturing: AAV Production In Suspension System

Source: Polyplus

FectoVIR®-AAV provides superior performance with the ability to reach highest AAV titers to increase the number of doses per batch. This scalable solution uses a robust and flexible reagent to support gene therapy from small to large scale production. We allow you to accelerate time to market by combine performance & scalability to reduce the time for process development.

access the Datasheet!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.

Subscribe to Cell & Gene X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Cell & Gene

Please tell us more about you so that we can customize our newsletters to your specific interests:

Polyplus